Endoscopic full-thickness suturing plus argon plasma mucosal coagulation versus argon plasma mucosal coagulation alone for weight regain after gastric bypass: a systematic review and meta-analysis.


Journal

Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505

Informations de publication

Date de publication:
12 2020
Historique:
received: 30 04 2020
accepted: 05 07 2020
pubmed: 22 7 2020
medline: 20 3 2021
entrez: 22 7 2020
Statut: ppublish

Résumé

Endoscopic transoral outlet reduction (TORe) has been used to manage weight regain after Roux-en-Y gastric bypass. We conducted a meta-analysis to summarize the efficacy and safety of the two most commonly used techniques: full-thickness suturing plus argon plasma mucosal coagulation (ft-TORe) and argon plasma mucosal coagulation alone (APMC-TORe). A literature search of publication databases was performed from their inception to February 2020 for relevant studies. The outcomes of interest were percentage total body weight loss, gastrojejunal anastomosis (GJA) diameter, and adverse events (AEs). The pooled effect estimates were analyzed using a random-effects model. Meta-regression was conducted to identify associations between GJA diameter and weight loss. Nine ft-TORe (n = 737) and 7 APMC-TORe (n = 888) studies were included. APMC-TORe was performed as a series of sessions (mean number of sessions ranging from 1.2 to 3), whereas ft-TORe was mostly performed as a single session. Percentage total body weight loss was 8.0% (95% confidence interval [CI], 6.3%-9.7%), 9.5% (95% CI, 8.1%-11.0%), and 5.8% (95% CI, 4.3%-7.1%) after ft-TORe and 9.0% (95% CI, 4.1%-13.9%), 10.2% (95% CI, 8.4%-12.1%), and 9.5% (95% CI, 5.7%-13.2%) after APMC-TORe at 3, 6, and 12 months, respectively, with no weight-loss difference at 3 and 6 months (P > .05). Only one severe AE was observed after APMC-TORe and none after ft-TORe. Stricture formation was the most common AE (ft-TORe 3.3% and APMC-TORe 4.8%, P = .38). All were successfully treated by endoscopic dilation or conservative treatment. Smaller aperture of the post-TORe GJA and greater change in the GJA diameter correlated with greater weight loss in APMC-TORe and numerical trends in ft-TORe. This meta-analysis demonstrates that both ft-TORe and APMC-TORe offer significant and comparable weight-loss outcomes with a high and comparable safety profile. However, APMC-TORe typically required multiple endoscopic sessions. Identifying a goal for the final and change in GJA diameter could be useful treatment targets.

Sections du résumé

BACKGROUND AND AIMS
Endoscopic transoral outlet reduction (TORe) has been used to manage weight regain after Roux-en-Y gastric bypass. We conducted a meta-analysis to summarize the efficacy and safety of the two most commonly used techniques: full-thickness suturing plus argon plasma mucosal coagulation (ft-TORe) and argon plasma mucosal coagulation alone (APMC-TORe).
METHODS
A literature search of publication databases was performed from their inception to February 2020 for relevant studies. The outcomes of interest were percentage total body weight loss, gastrojejunal anastomosis (GJA) diameter, and adverse events (AEs). The pooled effect estimates were analyzed using a random-effects model. Meta-regression was conducted to identify associations between GJA diameter and weight loss.
RESULTS
Nine ft-TORe (n = 737) and 7 APMC-TORe (n = 888) studies were included. APMC-TORe was performed as a series of sessions (mean number of sessions ranging from 1.2 to 3), whereas ft-TORe was mostly performed as a single session. Percentage total body weight loss was 8.0% (95% confidence interval [CI], 6.3%-9.7%), 9.5% (95% CI, 8.1%-11.0%), and 5.8% (95% CI, 4.3%-7.1%) after ft-TORe and 9.0% (95% CI, 4.1%-13.9%), 10.2% (95% CI, 8.4%-12.1%), and 9.5% (95% CI, 5.7%-13.2%) after APMC-TORe at 3, 6, and 12 months, respectively, with no weight-loss difference at 3 and 6 months (P > .05). Only one severe AE was observed after APMC-TORe and none after ft-TORe. Stricture formation was the most common AE (ft-TORe 3.3% and APMC-TORe 4.8%, P = .38). All were successfully treated by endoscopic dilation or conservative treatment. Smaller aperture of the post-TORe GJA and greater change in the GJA diameter correlated with greater weight loss in APMC-TORe and numerical trends in ft-TORe.
CONCLUSIONS
This meta-analysis demonstrates that both ft-TORe and APMC-TORe offer significant and comparable weight-loss outcomes with a high and comparable safety profile. However, APMC-TORe typically required multiple endoscopic sessions. Identifying a goal for the final and change in GJA diameter could be useful treatment targets.

Identifiants

pubmed: 32692991
pii: S0016-5107(20)34564-8
doi: 10.1016/j.gie.2020.07.013
pii:
doi:

Substances chimiques

Plasma Gases 0

Types de publication

Comparative Study Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1164-1175.e6

Informations de copyright

Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Auteurs

Veeravich Jaruvongvanich (V)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Kornpong Vantanasiri (K)

Department of Internal Medicine, University of Minnesota, Minneapolis, Minnesota.

Passisd Laoveeravat (P)

Department of Internal Medicine, Texas Tech University, Lubbock, Texas, USA.

Reem H Matar (RH)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Eric J Vargas (EJ)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Daniel B Maselli (DB)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Maryam Alkhatry (M)

Division of Gastroenterology, IBHO hospital, Ras Al Khaimah, United Arab Emirates.

Lea Fayad (L)

Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.

Vivek Kumbhari (V)

Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.

Ricardo Jose Fittipaldi-Fernandez (RJ)

Department of Bariatric Endoscopy, Endogastro Rio Clinic, Rio de Janeiro, RJ, Brazil.

Marcus Hollenbach (M)

Medical Department II - Gastroenterology, Hepatology, Infectious Diseases, Pulmonology - University of Leipzig Medical Center, Leipzig, Germany.

Rabindra R Watson (RR)

Interventional Endoscopy Services, California Pacific Medical Center, University of California, San Francisco, San Francisco, California, USA.

Luiz Gustavo de Quadros (L)

ABC Medical School, Santo André, Brazil.

Manoel Galvao Neto (M)

ABC Medical School, Santo André, Brazil.

Patrick Aepli (P)

Gastroenterology and Hepatology Unit, Luzerner Kantonsspital, Lucerne, Switzerland.

Dominic Staudenmann (D)

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Vitor Ottoboni Brunaldi (VO)

Gastrointestinal Endoscopy Unit, Gastroenterology Department, University of São Paulo Medical School, São Paulo, Brazil.

Andrew C Storm (AC)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

John A Martin (JA)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Victoria Gomez (V)

Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, Florida, USA.

Barham K Abu Dayyeh (BK)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH